Inferra AIResearch Tools

Inferra AI / Company / IMNM

Immunome Inc.

IMNM · Health Care

Last earnings Aug 11, 2026

AI analysis

Q2 2025 · reported Aug 6, 2025

Based on: Earnings release + parent 8-K + 10-Q — transcript not held

No extracted figures held

The event-summary record for this company carries no extracted figures, so the brief and charts cannot be drawn yet. The summary below and the held documents are the record for this event.

Guidance · company-stated

No guidance located in the held release

Next earningsNo verified date on fileNo date is estimated or imported

Capital allocation

The Company expects that its existing cash, cash equivalents and marketable securities at June 30, 2026 will be sufficient to fund its current and planned operating expenses and capital expenditures for at least 12 months from the filing date of this Quarterly Report on Form 10-Q.

Beyond that date, the Company may need to raise additional capital through a combination of equity offerings, debt financings, collaborations, strategic alliances and licensing arrangements to achieve its longer-term business objectives.

General educational research only — not investment advice.Every figure is as stated in the held documents; values marked “computed from stated figures” are arithmetic on those stated figures. Guidance shown is the company’s own stated guidance. No price targets, no recommendations, no consensus estimates.

Event summary

Immunome Reports Second Quarter 2025 Financial Results and Provides Business Update 8/6/2025

Based on: Earnings release + parent 8-K + 10-Q — transcript not held

Guidance & outlook

No guidance located in the held release

Capital allocation

The Company expects that its existing cash, cash equivalents and marketable securities at June 30, 2026 will be sufficient to fund its current and planned operating expenses and capital expenditures for at least 12 months from the filing date of this Quarterly Report on Form 10-Q.

SEC original ↗Immunome Inc. — 10-Q Quarterly report10-QAug 11, 2026

Beyond that date, the Company may need to raise additional capital through a combination of equity offerings, debt financings, collaborations, strategic alliances and licensing arrangements to achieve its longer-term business objectives.

SEC original ↗Immunome Inc. — 10-Q Quarterly report10-QAug 11, 2026

Strategy & priorities

(Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced financial results for the quarter ended June 30, 2025 and provided a business update.

SEC original ↗Immunome Inc. — Earnings release (8-K exhibit)EX-99Aug 6, 2025

The trial is an open-label, multicenter dose-escalation and expansion study that is expected to include participants with advanced B-cell lymphomas and advanced solid tumors.

SEC original ↗Immunome Inc. — Earnings release (8-K exhibit)EX-99Aug 6, 2025

Since its inception, the Company has devoted substantially all its resources to research and development, raising capital, building its management team, expanding its intellectual property portfolio, and executing strategic partnerships and transactions.

SEC original ↗Immunome Inc. — 10-Q Quarterly report10-QAug 11, 2026

Beyond that date, the Company may need to raise additional capital through a combination of equity offerings, debt financings, collaborations, strategic alliances and licensing arrangements to achieve its longer-term business objectives.

SEC original ↗Immunome Inc. — 10-Q Quarterly report10-QAug 11, 2026

Strategic transactions and agreements Ayala Pharmaceuticals On March 25, 2024, the Company and Ayala Pharmaceuticals, Inc.

SEC original ↗Immunome Inc. — 10-Q Quarterly report10-QAug 11, 2026

Risks & headwinds

The Company is subject to risks and uncertainties common to companies in the biotechnology industry at Immunome's stage including, but not limited to, risks associated with research, development, and manufacturing activities, uncertain results of preclinical and clinical testing, development of new technological innovations and products by competitors, dependence on key personnel, partners and third-party vendors, protection of proprietary technology, compliance with government regulations, regulatory approval of products and the ability to secure additional capital to fund operations.

SEC original ↗Immunome Inc. — 10-Q Quarterly report10-QAug 11, 2026

Forward-Looking Statements In addition to historical financial information, this discussion contains forward-looking statements based upon current expectations that involve risks and uncertainties.

SEC original ↗Immunome Inc. — 10-Q Quarterly report10-QAug 11, 2026

Competitors

Competitors & peers

Same GICS sector — classification peers, not declared competitors

Gilead Sciences (GILD) Health CareGenmab (GMAB) Health CareAlcon (ALC) Health CareArgenx (ARGX) Health CareSanofi (SNY) Health CareMerck & Co. (MRK) Health CareXencor Inc (XNCR) Health CareIllumina, Inc. (ILMN) Health Care
Documents

Filings

30 documents

Earnings releases

11 documents

Presentations

0 documents

No presentations for Immunome Inc. are held in this edition of the library.

Transcripts

0 documents

No transcripts for Immunome Inc. are held in this edition of the library.

Mentioned by

1 company

Other tracked companies whose held documents mention Immunome Inc. by name or ticker. A mention is counted once per document, from the document text the library holds.

See also the earnings calendar for every tracked company’s next earnings date.